RANCHO CORDOVA, Calif., Feb. 9, 2012 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, today reported results for the second quarter of fiscal 2012.
For the quarter ended December 31, 2011, the Company reported sales of $4.8 million. This compares to revenues of $5.9 million in the second quarter a year ago and $4.9 million in the prior quarter. Disposable sales in the second quarter of fiscal 2012 were $3.5 million, compared to $3.4 million a year ago and $3.5 million in the prior quarter. ThermoGenesis reported a net loss of $1.3 million, or $0.08 per share, in the second quarter of fiscal 2012, compared to a net loss of $486,000, or $0.03 per share, in the same period a year ago.
"Although our BioArchive sales were noticeably affected by the continuing debt crisis versus the quarter a year ago, we are pleased with our progress along the strategic front, having signed a major development and distribution deal with Arthrex, and having published positive clinical data regarding the safety and efficacy of our Res-Q bone marrow concentration system," said Matthew Plavan the Company's Chief Executive Officer.
The Company ended the quarter with $8.7 million in cash compared with $12.3 million at the end of fiscal 2011.
For the first six months of fiscal 2012, ThermoGenesis reported revenues of $9.6 million compared to revenues of $12.9 million in the first six months of fiscal 2011. The Company reported a net loss of $2.5 million, or $0.15 per share, compared to a net loss of $554,000, or $0.04 per share, in the same period a year ago.
Plavan noted the Company had recently realized several important milestones, including:
On January 30, 2012, the Company announced it had implemented changes in management responsibilities to maximize its progress toward its strategic goals. Plavan was named Chief Executive Officer and a member of the board of directors, while retaining his position as Chief Financial Officer. He replaced J. Melville Engle, who retired from his position as Chairman and Chief Executive Officer. The Company also eliminated eight additional positions.
"As we indicated at that time, our board of directors believed structural changes were necessary if the Company was going to achieve its short-term objectives and be positioned for long-term growth. These changes are designed to recalibrate our resources to current revenues and the cadence of new market opportunities, while continuing to support our product quality and development, customer service and business development initiatives," Plavan said.
Company's Conference Call and Webcast
Management will hold a conference call today at 2 p.m., Pacific (5 p.m., Eastern) to review the fiscal 2012 second quarter results.Conference call details: Dial-in (U.S.):1-800-860-2442 Dial-in (Internationally):1-412-858-4600 Conference Name:"ThermoGenesis"To listen to the audio webcast of the call during or after the event, please visit http://www.thermogenesis.com/investors-webcasts-and-calls.aspx
An audio replay of the conference call will be available beginning approximately two hours after completion of the call for the following five business days.
To access the replay: Access number (U.S.):1-877-344-7529 Access number (Internationally)1-412-317-0088 Conference ID#:385107About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:
This press release contains forward-looking statements. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA and foreign regulatory approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2012, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2012. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Web site: http://www.thermogenesis.com
Contact: Investor Relations
Condensed Consolidated Balance Sheets
2011ASSETSCurrent assets: Cash and cash equivalents$8,729,000$12,309,000 Accounts receivable, net4,981,0003,963,000 Inventories6,790,0006,348,000 Other current assets170,000420,000Total current assets20,670,00023,040,000Equipment1,589,0001,310,000Other assets48,00049,000$22,307,000$24,399,000LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities: Accounts payable$1,648,000$1,791,000 Other current liabilities2,204,0002,273,000Total current liabilities3,852,0004,064,000Long-term liabilities227,000242,000Stockholders' equity18,228,00020,093,000$22,307,000$24,399,000THERMOGENESIS CORP.
Condensed Consolidated Statements of Operations
(Unaudited)Three Months Ended,
December 31,Six Months Ended,
December 31,2011201020112010Net revenues$4,775,000$5,860,000$9,634,000$12,857,000Cost of revenues3,071,0003,504,0005,931,0007,906,000 Gross profit1,704,0002,356,0003,703,0004,951,000Expenses: Selling, general and administrative1,991,0002,333,0004,307,0004,273,000 Research and development1,037,000774,0001,960,0001,499,000Total operating expenses3,028,0003,107,0006,267,0005,772,000Interest and other income, net46,000265,00078,000267,000Net loss($1,278,000)($486,000)($2,486,000)($554,000)Basic and diluted net loss per common share($0.08)($0.03)($0.15)($0.04)Shares used in computing per share data16,378,03314,048,64916,370,53314,035,960THERMOGENESIS CORP.
Condensed Consolidated Statements of Cash Flows
(Unaudited)Six Months Ended
December 31,20112010Cash flows from operating activities: Net loss($2,486,000)($554,000) Adjustments to reconcile net loss to net
cash used in operating activities:Depreciation and amortization202,000248,000Stock based compensation expense621,000607,000Gain on disposal of equipment--(7,000)Net change in operating assets and liabilities:Accounts receivable, net(1,018,000)841,000Inventories(322,000)(622,000)Other current assets130,00080,000Other assets1,00040,000Accounts payable(143,000)(369,000)Other current liabilities(84,000)(782,000)Net cash used in operating activities(3,099,000)(518,000)Cash flows from investing activities: Capital expenditures(481,000)(35,000) Proceeds from sale of equipment--17,000Net cash used in investing activities:(481,000)(18,000)Cash flows from financing activities: Exercise of stock options--7,000 Payments on capital lease obligations--(1,000)Net cash provided by financing activities--6,000Net decrease in cash and cash equivalents(3,580,000)(530,000)Cash and cash equivalents at beginning of period12,309,00010,731,000Cash and cash equivalents at end of period$8,729,000$10,201,000
|SOURCE ThermoGenesis Corp.|
Copyright©2010 PR Newswire.
All rights reserved